With a market cap of $10.8 billion, Charles River Laboratories International, Inc. (CRL) is a global partner to pharmaceutical and biotechnology companies, government agencies, and leading academic institutions, providing essential products and services that accelerate research and drug development. With a dedicated team focused on innovation and quality, the company helps clients expedite the discovery, early-stage development, and safe manufacture of new therapies for patients worldwide.
The Wilmington, Massachusetts-based company is slated to announce its fiscal Q2 2026 results before the market opens on Wednesday, Aug. 5. Ahead of the event, analysts expect CRL to report an adjusted EPS of $2.72, down 12.8% from $3.12 in the year-ago quarter. However, the company has surpassed Wall Street's bottom-line estimates in each of the past four quarterly reports.
